TICKERNERD
Menu
CAHCAHHealthcare · Medical Distribution

CAH Stock Forecast: Cardinal Health, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$225
−0.42% on the day

The 18 Wall Street analysts covering Cardinal Health, Inc. hold a median 12-month price target of $276 — +22.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$52.4B
Ticker Nerd rank
96 / 100
Median analyst target
$276
Analysts covering
18
Revenue$63.7B+5.8% y/y
Operating income$814.0M
Net income$400.0M
Free cash flow$1.4B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−4.1%
YTD
+10.5%
1Y
+51.8%
From 52W high
−9.3%
From 52W low
+54.4%
$146
$249
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardinal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Momentum
90
Value
88
Quality
84
Revisions
80
Accruals
71
Growth
70
Issuance
69
Size
5

Volatility (97): The share price has been relatively steady.

Issuance (69): The company has been issuing shares or taking on financing, diluting existing holders.

Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Oct 25Jan 26Apr 26Jul 26CAHHigh $292Median $276Low $235

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
15 Buy3 Hold0 Sell
Low $235Median $276High $292

The green dot is the last close — the median target sits +22.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 15 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Aug 2026RBC CapitalInitiatesOutperform$276
13 Aug 2026BarclaysMaintainsOverweight$258 → $275
13 Aug 2026JP MorganMaintainsNeutral$215 → $260
13 Aug 2026TD CowenMaintainsBuy$275 → $280
12 Aug 2026BairdMaintainsOutperform$251 → $274
12 Aug 2026CitigroupMaintainsBuy$265 → $280
12 Aug 2026Evercore ISI GroupMaintainsOutperform$265 → $270
12 Aug 2026MizuhoMaintainsOutperform$240 → $250
12 Aug 2026Morgan StanleyMaintainsOverweight$255 → $265
12 Aug 2026UBSMaintainsBuy$274 → $280
12 Aug 2026Wells FargoMaintainsOverweight$245 → $277
24 July 2026CitigroupMaintainsBuy$245 → $265
24 July 2026CitigroupMaintainsBuy—
23 July 2026MizuhoMaintainsOutperform—
23 July 2026MizuhoMaintainsOutperform$235 → $240
20 July 2026UBSMaintainsBuy—
20 July 2026UBSMaintainsBuy$260 → $274
9 July 2026TD CowenMaintainsBuy$255 → $275
9 July 2026TD CowenMaintainsBuy—
2 July 2026B of A SecuritiesMaintainsBuy$240 → $260

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CAH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Cardinal Health, Inc. returned +51.8% against +16.3% for the S&P 500, dividends included.

CAH vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Oct 25Jan 26Apr 26Jul 26CAHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CAH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.8%
Analysts raising
16
Analysts cutting
0
Fundamentals

Cardinal Health, Inc. (CAH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.2×

Cheaper than 24% of US stocks

Price / sales
0.2×

Cheaper than 92% of US stocks

Price / book
−19.3×

Cheaper than 98% of US stocks

EV / EBITDA
13.6×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 41% of US stocks

Earnings growth (YoY)
66.5%

Higher than 79% of US stocks

Gross margin
4.0%

Higher than 6% of US stocks

Operating margin
1.3%

Higher than 47% of US stocks

Net margin
0.7%

Higher than 48% of US stocks

Returns & dividend
Return on equity
−62.9%

Higher than 18% of US stocks

Return on assets
3.7%

Higher than 69% of US stocks

Dividend yield
0.9%

Higher than 20% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cardinal Health, Inc. (CAH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cardinal Health, Inc. has a market value of $52.4B and an enterprise value of $57.7B.

  • Revenue in the twelve months to 30 June 2026: $254.2B. The latest quarter grew 5.8% year on year.

  • Net income over the same four quarters: $1.7B, a 0.7% net margin.

  • Diluted earnings per share, trailing twelve months: $7.24.

  • Free cash flow in the twelve months to 30 June 2026: $4.5B.

  • Cardinal Health, Inc. spent $1.4B on share buybacks and $491.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 233.0M.

  • Trailing P/E: 31.2×; forward P/E: 16.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.92%, paying out 28% of earnings.

  • Cardinal Health, Inc. employs 58,788 people — $4.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

CAH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
CAHCardinal Health, Inc.$52.4B
96
CORCencora, Inc.$59.9B
70
MCKMcKesson Corp.$102.4B
86
HSICHenry Schein, Inc.$9.7B
81
NTRANatera, Inc.*$51.0B
81
EWEdwards Lifesciences Corp.*$50.8B
91
BDXBecton, Dickinson & Co.*$49.9B
93

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardinal Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAH news & analysis

Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds

MarketBeat · 19 Sept 2026positive

Cardinal Health CEO Jason Hollar said the company expects fiscal 2027 to extend the operating momentum generated in fiscal 2026, with all five operating segments positioned for a "constructive" period. The company is targeting 13%-15% EPS growth as its specialty business builds momentum.

Why it matters — CAH watchers would be interested because the CEO's comments signal continued growth and stability across all of the company's operating segments into fiscal 2027.

Cardinal Health Sees Growth Normalize as Specialty, At-Home Investments Expand

MarketBeat · 19 Sept 2026positive

Cardinal Health CEO Jason Hollar said fiscal 2026 performance was supported by double-digit earnings growth across all five operating segments. Fiscal 2027 guidance reflects continued growth from a more normalized base as the company expands its specialty and at-home investments.

Why it matters — The outlook signals continued broad-based, normalized earnings growth across Cardinal Health's segments, giving watchers insight into the company's trajectory after a period of higher-growth expansion.

Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?

Zacks Investment Research · 16 Sept 2026neutral

Cardinal Health expects IRA pricing changes to pressure its Pharma revenues while aiming to protect profitability through compensation and durable distribution agreements.

Why it matters — A CAH watcher would care because IRA pricing changes could affect Pharma segment revenues and how well the company can preserve its margins.

Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Investment Research · 15 Sept 2026negative

Cardinal Health (CAH) shares settled at $232.36 on the latest trading day, a decline of 1.08% from the previous close, representing a larger fall than the broader market.

Why it matters — A CAH watcher would care because the stock underperformed the wider market on the day, signaling relative weakness worth monitoring.

Cardinal Health, Inc. (CAH) Presents at 2026 Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Cardinal Health, Inc. (CAH) presented at the 2026 Global Healthcare Conference, with a transcript of the presentation made available via Seeking Alpha. The news item consists solely of this conference presentation transcript.

Why it matters — The conference presentation transcript offers CAH watchers direct insight into management's remarks and commentary at a major healthcare industry event.

FAQ

Frequently asked questions about CAH stock

What is the CAH stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Cardinal Health, Inc. have a median 12-month price target of $276, with estimates ranging from $235 to $292. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAH stock a buy right now?

Of the 18 analysts covering Cardinal Health, Inc., 15 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardinal Health, Inc. 96 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAH?

As at 19 Sept 2026, Cardinal Health, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will CAH stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +22.2% from the last close, and Ticker Nerd's factor model ranks Cardinal Health, Inc. 96 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAH stock forecast for 2030?

No analyst covering Cardinal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $235 to $292 over the next 12 months.

How has CAH stock performed over the past year?

Cardinal Health, Inc. returned +51.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardinal Health, Inc. do?

Cardinal Health Inc. is a healthcare services and products company that supports hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home.

What is the latest news on CAH?

The most recent item we track (MarketBeat, 19 Sept 2026): "Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds". Cardinal Health CEO Jason Hollar said the company expects fiscal 2027 to extend the operating momentum generated in fiscal 2026, with all five operating segments positioned for a "constructive" period. The company is targeting 13%-15% EPS growth as its specialty business builds momentum.

Company

About Cardinal Health, Inc.

Cardinal Health Inc. is a healthcare services and products company that supports hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home. It distributes branded, generic, specialty, and over-the-counter pharmaceuticals, while also providing pharmacy management, inventory, logistics, and data-driven supply chain services. The company manufactures and distributes medical, surgical, and laboratory products, including procedure kits, gloves, needles, wound care items, and other clinical supplies. Cardinal Health also operates specialty pharmacy and radiopharmaceutical services that support complex care settings. Through its two main segments, Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution, Cardinal Health plays a central role in connecting manufacturers, providers, and care sites across the healthcare supply chain.

CEO Mr. Jason M. Hollar · 58,788 employees · United States · https://www.cardinalhealth.com